BRIEF-Aurinia's Voclosporin meets primary endpoint

Mon Aug 15, 2016 6:10am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 15 (Reuters) - Aurinia Pharmaceuticals Inc :

* Aurinia Pharmaceuticals announces voclosporin meets primary endpoint in phase IIB Aura-LV study in Lupus Nephritis

* Trial achieved its primary endpoint, demonstrating statistically significantly greater complete remission

* Plans to meet with U.S. FDA in q4 to discuss data and drug's subsequent clinical development and path to registration in ln Source text for Eikon: Further company coverage: